Merck & Co.
MRK
$140.93
-0.63%
Merck & Co., Inc. is a global pharmaceutical giant that develops and manufactures prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, cardiometabolic disease, infectious disease, and immunology, with its immuno-oncology franchise led by Keytruda serving as the single largest revenue driver alongside a substantial vaccine portfolio anchored by Gardasil. The company is a top-tier, blue-chip player in the Drug Manufacturers - General industry, distinguished by the scale of its oncology platform, a deep late-stage pipeline, and roughly 53% of human health sales generated in the United States. The current investor narrative is dominated by two competing forces: an extraordinary share-price re-rating (up more than 66% over the past year) driven by pipeline catalysts such as positive Phase IIb tulisokibart data in hidradenitis suppurativa and a blowout August move, set against a patent-cliff overhang tied to Keytruda and a European legal setback in which Halozyme won a court order blocking Merck's subcutaneous Keytruda formulation. Debate now centers on whether the pipeline can replace looming Keytruda losses fast enough to justify the stock's premium, while a swing to GAAP losses in the first half of 2026 (driven by large acquisition-related and other charges) has muddied headline earnings and shifted investor focus toward adjusted EPS and free cash flow.…
MRK
Merck & Co.
$140.93
Related headlines
MRK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $159.76 and implied upside of +13.4% versus the current price.
Average Target
$159.76
0 analysts
Implied Upside
+13.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $186
Analyst target range
Bulls vs Bears: MRK Investment Factors
The bull case currently has stronger evidence: a 66.6% one-year return, 53.5 points of relative strength versus SPY, $16.1 billion of TTM free cash flow, a 15.7x forward PE, and a buy consensus with a $158.56 average target all point to a franchise that is being re-rated on pipeline progress rather than deteriorating fundamentals. The bear case rests on a genuine structural threat — Keytruda's patent cliff compounded by the European loss on subcutaneous Keytruda — plus messy GAAP earnings from acquisition charges. The single most important tension is whether tulisokibart and the late-stage pipeline can scale fast enough to offset Keytruda erosion before 2028-2030; every other debate (valuation, momentum, dividend) is downstream of that one question. If pipeline data keeps hitting endpoints, the stock can justify a premium; if a Phase III disappoints or the SC Keytruda setback spreads to other geographies, the re-rating unwinds quickly.
Bullish
- Analyst target implies 9.1% upside: The 25-analyst consensus is a 'buy' (mean recommendation 1.78) with an average target of $158.56 versus the current $145.27, implying roughly 9.1% upside, and a high target of $186 implying 28%. Even the low target of $105 sits only 27.7% below spot, suggesting the sell-side sees a bounded downside.
- Massive relative strength vs. market: MRK is up 66.6% over one year versus SPY's 13.1%, a relative strength of +53.5 points, and is up 36.5% YTD against SPY's 11.5%. The 6-month relative strength of +23.4 confirms this is a sustained re-rating, not a one-off spike.
- Cash generation and margins remain elite: TTM free cash flow is $16.06 billion with a 28.1% net margin, 36.2% operating margin, and 72.0% gross margin. Q2 2026 gross margin of 73.5% actually improved versus Q2 2025's 75.7% on a comparable basis while revenue grew 5.1% YoY to $16.61 billion.
- Valuation is cheap on forward earnings: Forward PE of 15.7x against trailing PE of 14.4x and a PEG of 1.81 is undemanding for a franchise with 72% gross margins and a 3.1% dividend yield. EV/EBITDA of 10.6x and PS of 4.06x are reasonable for a large-cap pharma with an oncology leadership position.
Bearish
- Keytruda patent cliff is existential: Keytruda is the single largest revenue driver, and the company's own narrative flags a patent-cliff overhang. A 72% gross margin franchise losing its biggest product creates a multi-billion-dollar revenue hole that the pipeline must fill, and no current asset is remotely the size of Keytruda.
- European legal loss on subcutaneous Keytruda: Halozyme won a court order blocking Merck's subcutaneous Keytruda formulation in Europe (Oct 8, 2026). This removes a key lifecycle-extension strategy in a major market and could delay or reduce revenue from the SC formulation, weakening the defense against biosimilar erosion.
- GAAP losses and earnings quality deterioration: Q1 2026 EPS was -$1.72 and Q2 2026 EPS was -$0.54, with H1 2026 net losses of $4.24 billion and $1.34 billion respectively, driven by acquisition-related charges. Trailing EPS of $0.069 makes the 14.4x trailing PE meaningless and forces investors to rely on adjusted numbers, raising the risk of negative headline surprises.
- Stock is extended after a 66% run: At $145.27 the stock sits just 7.4% below its 52-week high of $156.92 and 77% above its 52-week low of $82.01. The 1-month change is -1.9% with relative strength of -0.88 versus SPY, suggesting momentum has stalled near resistance.
MRK Technical Analysis
Beta
0.22
0.22x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$82-$157
Price range past year
Annual Return
+61.9%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | -5.2% | +0.9% |
| 3m | +8.6% | +4.1% |
| 6m | +25.7% | +7.2% |
| 1y | +61.9% | +12.4% |
| ytd | +32.4% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Quarterly Revenue
$16.6B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
73.5%
Latest Quarter
Free Cash Flow
$16.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
PE
14.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 9x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and concentration. H1 2026 produced GAAP net losses of $4.24 billion (Q1) and $1.34 billion (Q2), with Q2 operating income of -$683 million despite $16.61 billion of revenue, because R&D of $9.74 billion and acquisition-related charges overwhelmed a 73.5% gross margin. Trailing EPS of $0.069 is effectively zero, so the 14.4x trailing PE is not a real valuation anchor; investors are underwriting $9.89 of estimated 2026 EPS that depends on excluding large charges. Meanwhile debt-to-equity of 0.96 and $525 million of quarterly interest expense add fixed costs, and revenue remains heavily concentrated in Keytruda, whose patent cliff is the dominant long-term risk.
Market and competitive risks are dominated by valuation compression and legal/regulatory setbacks. The stock trades at 5.0x book and 4.06x sales after a 66.6% one-year run, leaving little room for disappointment; a beta of only 0.222 means it will not be rescued by a broad market rally, and its -0.88 one-month relative strength shows money already rotating elsewhere. The Halozyme court order blocking subcutaneous Keytruda in Europe (Oct 8, 2026) is a concrete competitive/legal threat that could extend to other jurisdictions and undercut a key lifecycle strategy. Sector rotation is also a factor: peers like Bristol Myers Squibb are being pitched on discounted valuations, and AstraZeneca's pipeline setbacks show how quickly sentiment in large-cap pharma can reverse.
The worst-case scenario is a pipeline failure combined with faster-than-expected Keytruda erosion: a Phase III tulisokibart miss, expansion of the European SC Keytruda injunction, and biosimilar entry hitting revenue while acquisition charges keep GAAP earnings negative. In that chain, the stock would retest its 52-week low of $82.01, roughly 43.5% below the current $145.27, and could approach the analyst low target of $105 (-27.7%). The observed max drawdown in the data is only -11.9%, but that reflects the recent uptrend; a patent-cliff repricing would be far deeper, and an investor could realistically lose 25-45% from current levels in the adverse case.